Literature DB >> 29232540

Early Relapse in Follicular Lymphoma: High Risks and High Stakes.

Brian K Link1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 29232540      PMCID： PMC5728365          DOI： 10.1200/JOP.2017.028357

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  9 in total

1.  Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Authors:  Marcie R Tomblyn; Marian Ewell; Christopher Bredeson; Brad S Kahl; Stacey A Goodman; Mary M Horowitz; Julie M Vose; Robert S Negrin; Ginna G Laport
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-10       Impact factor: 5.742

2.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Authors:  Nathan H Fowler; R Eric Davis; Seema Rawal; Loretta Nastoupil; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle A Fanale; Luis E Fayad; Jason R Westin; Jatin Shah; Robert Z Orlowski; Michael Wang; Francesco Turturro; Yasuhiro Oki; Linda C Claret; Lei Feng; Veerabhadran Baladandayuthapani; Tariq Muzzafar; Kenneth Y Tsai; Felipe Samaniego; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

3.  Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Authors:  Ajay K Gopal; Brad S Kahl; Christopher R Flowers; Peter Martin; Stephen M Ansell; Esteban Abella-Dominicis; Brian Koh; Wei Ye; Paul M Barr; Gilles A Salles; Jonathan W Friedberg
Journal:  Blood       Date:  2017-03-21       Impact factor: 22.113

4.  Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?

Authors:  Mehdi Hamadani; Mary M Horowitz
Journal:  J Oncol Pract       Date:  2017-12       Impact factor: 3.840

5.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

Authors:  Carla Casulo; Michelle Byrtek; Keith L Dawson; Xiaolei Zhou; Charles M Farber; Christopher R Flowers; John D Hainsworth; Matthew J Maurer; James R Cerhan; Brian K Link; Andrew D Zelenetz; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

6.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.

Authors:  Matthew J Maurer; Emmanuel Bachy; Hervé Ghesquières; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; David J Inwards; Cristine Allmer; Catherine Chassagne-Clément; Emmanuelle Nicolas-Virelizier; Catherine Sebban; Laure Lebras; Clementine Sarkozy; William R Macon; Andrew L Feldman; Sergei I Syrbu; Alexandra Traverse-Glehan; Bertrand Coiffier; Susan L Slager; George J Weiner; Thomas E Witzig; Thomas M Habermann; Gilles Salles; James R Cerhan; Brian K Link
Journal:  Am J Hematol       Date:  2016-09-03       Impact factor: 10.047

7.  Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.

Authors:  Ginna G Laport; Juan Wu; Brent Logan; Veronika Bachanova; Chitra Hosing; Timothy Fenske; Walter Longo; Steven M Devine; Auayporn Nademanee; Iris Gersten; Mary Horowitz; Hillard M Lazarus; Marcie L Riches
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-23       Impact factor: 5.742

8.  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Authors:  Martin Dreyling; Armando Santoro; Luigina Mollica; Sirpa Leppä; George A Follows; Georg Lenz; Won Seog Kim; Arnon Nagler; Panayiotis Panayiotidis; Judit Demeter; Muhit Özcan; Marina Kosinova; Krimo Bouabdallah; Franck Morschhauser; Don A Stevens; David Trevarthen; Marius Giurescu; Lisa Cupit; Li Liu; Karl Köchert; Henrik Seidel; Carol Peña; Shuxin Yin; Florian Hiemeyer; Jose Garcia-Vargas; Barrett H Childs; Pier Luigi Zinzani
Journal:  J Clin Oncol       Date:  2017-10-04       Impact factor: 44.544

9.  A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Authors:  P Martin; S-H Jung; B Pitcher; N L Bartlett; K A Blum; T Shea; E D Hsi; J Ruan; S E Smith; J P Leonard; B D Cheson
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.